Business Snapshot & Market Position

This section provides a high-level snapshot of Novo Nordisk's current market standing, financial health, and revenue distribution. As a pioneer in diabetes care and the current leader in the GLP-1 obesity market (Wegovy, Ozempic), understanding NVO's revenue drivers and historical growth trajectory is critical before diving into complex valuation metrics. The charts below illustrate their massive growth phase and reliance on metabolic disease treatments.